Literature DB >> 26201528

Low incidence and prevalence of primary biliary cirrhosis in Canterbury, New Zealand: a population-based study.

Jing Hieng Ngu1,2, Richard Blair Gearry1,2, Andrew Jeffrey Wright2, Catherine Ann Malcolm Stedman3,4.   

Abstract

PURPOSE: Epidemiological data on primary biliary cirrhosis (PBC) in the Southern Hemisphere is scarce. Our aim was to perform a population-based epidemiological study of PBC in Canterbury, New Zealand.
METHODS: Multiple case-finding methods were employed. All public and private, adult and pediatric outpatient clinics, hospital discharge summaries, and laboratory and pathology reports were searched to identify all cases in the region. Cases were included if at least two of the following criteria were fulfilled: (1) positive anti-mitochondrial antibodies, (2) elevated alkaline phosphatase for greater than 6 months, and (3) compatible liver histology.
RESULTS: A total of 71 cases of PBC were included. The incidence in 2008 was 0.8 (95% confidence interval (CI) 0.1-1.6) per 100,000. The point prevalence on December 31, 2008 was 9.9 (95% CI 7.1-12.7) per 100,000. Male to female ratio was 1:11. At presentation, 45% were asymptomatic. Age at diagnosis peaked at the seventh decade with mean age at diagnosis of 61 (95% CI 58-64).
CONCLUSIONS: This is the first population-based epidemiological study of PBC conducted in New Zealand and only the second in the Southern Hemisphere. The incidence and prevalence are lower than the Northern Hemisphere, even though the majority of our population has shared genetic background with some of these countries. Our study has provided further support to the hypothesis that there may be a protective effect or lack of a risk factor for PBC in New Zealand.

Entities:  

Keywords:  Epidemiology; Incidence; Prevalence; Primary biliary cirrhosis

Year:  2011        PMID: 26201528     DOI: 10.1007/s12072-011-9329-0

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  22 in total

1.  Incidence and prevalence of primary biliary cirrhosis in the city of Newcastle upon Tyne, England.

Authors:  J V Metcalf; R S Bhopal; J Gray; D Howel; O F James
Journal:  Int J Epidemiol       Date:  1997-08       Impact factor: 7.196

2.  Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences.

Authors:  Edward V Loftus
Journal:  Gastroenterology       Date:  2004-05       Impact factor: 22.682

3.  Epidemiology of primary biliary cirrhosis in Victoria, Australia: high prevalence in migrant populations.

Authors:  Siddharth Sood; Paul J Gow; John M Christie; Peter W Angus
Journal:  Gastroenterology       Date:  2004-08       Impact factor: 22.682

4.  High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study.

Authors:  Richard B Gearry; Ann Richardson; Christopher M A Frampton; Judith A Collett; Michael J Burt; Bruce A Chapman; Murray L Barclay
Journal:  Inflamm Bowel Dis       Date:  2006-10       Impact factor: 5.325

5.  The epidemiology of Wegener's granulomatosis and microscopic polyangiitis in a Southern Hemisphere region.

Authors:  A Gibson; L K Stamp; P T Chapman; J L O'Donnell
Journal:  Rheumatology (Oxford)       Date:  2005-12-20       Impact factor: 7.580

Review 6.  The geoepidemiology of primary biliary cirrhosis.

Authors:  J Metcalf; O James
Journal:  Semin Liver Dis       Date:  1997-02       Impact factor: 6.115

7.  Epidemiology and natural history of primary biliary cirrhosis in a US community.

Authors:  W R Kim; K D Lindor; G R Locke; T M Therneau; H A Homburger; K P Batts; B P Yawn; J L Petz; L J Melton; E R Dickson
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

8.  Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis.

Authors:  Jing Hieng Ngu; Richard Blair Gearry; Andrew Jeffrey Wright; Catherine Ann Malcolm Stedman
Journal:  Clin Gastroenterol Hepatol       Date:  2011-09-03       Impact factor: 11.382

9.  Incidence, prevalence and clinical course of primary biliary cirrhosis in a Spanish community.

Authors:  Xavier Pla; Mercedes Vergara; Montserrat Gil; Blai Dalmau; Berta Cisteró; Rosa M Bella; Jordi Real
Journal:  Eur J Gastroenterol Hepatol       Date:  2007-10       Impact factor: 2.566

10.  Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: a population-based study.

Authors:  Robert P Myers; Abdel Aziz M Shaheen; Andrew Fong; Kelly W Burak; Alex Wan; Mark G Swain; Robert J Hilsden; Lloyd Sutherland; Hude Quan
Journal:  Hepatology       Date:  2009-12       Impact factor: 17.425

View more
  5 in total

1.  Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis.

Authors:  Na Zeng; Weijia Duan; Sha Chen; Shanshan Wu; Hong Ma; Xiaojuan Ou; Hong You; Yuanyuan Kong; Jidong Jia
Journal:  Hepatol Int       Date:  2019-09-25       Impact factor: 6.047

2.  Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland.

Authors:  Benedetta Terziroli Beretta-Piccoli; Guido Stirnimann; Andreas Cerny; David Semela; Roxane Hessler; Beat Helbling; Felix Stickel; Carolina Kalid-de Bakker; Florian Bihl; Emiliano Giostra; Magdalena Filipowicz Sinnreich; Carl Oneta; Adriana Baserga; Pietro Invernizzi; Marco Carbone; Joachim Mertens
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

Review 3.  PBC: No Longer a Western Disease?

Authors:  Atsushi Tanaka
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-01-13

4.  National incidence of autoimmune liver diseases and its relationship with the human development index.

Authors:  Hong-Ying Pan; Yi-Ning Dai; Ji-Na Zheng; Ke-Qing Shi; Sven Van Poucke; Hai Zou; Ming-Hua Zheng
Journal:  Oncotarget       Date:  2016-07-19

5.  APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis.

Authors:  Hong You; Xiong Ma; Cumali Efe; Guiqiang Wang; Sook-Hyang Jeong; Kazumichi Abe; Weijia Duan; Sha Chen; Yuanyuan Kong; Dong Zhang; Lai Wei; Fu-Sheng Wang; Han-Chieh Lin; Jin Mo Yang; Tawesak Tanwandee; Rino A Gani; Diana A Payawal; Barjesh C Sharma; Jinlin Hou; Osamu Yokosuka; A Kadir Dokmeci; Darrell Crawford; Jia-Horng Kao; Teerha Piratvisuth; Dong Jin Suh; Laurentius A Lesmana; Jose Sollano; George Lau; Shiv K Sarin; Masao Omata; Atsushi Tanaka; Jidong Jia
Journal:  Hepatol Int       Date:  2022-02-04       Impact factor: 6.047

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.